Teclistamab maintenance, given alone or in combination with lenalidomide, demonstrated “unprecedented efficacy” in multiple myeloma patients.

By reducing cytokine release syndrome and neurotoxicity, prophylactic tocilizumab could facilitate safe outpatient ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

(MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a ...

IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®▼ (teclistamab) from two investigational studies in patients with newly diagnosed ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...

"At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're ...

3 "Teclistamab was the first BCMA bispecific therapy approved as monotherapy for relapsed and refractory multiple myeloma and plays an important role in our approach to transform outcomes for all ...

1Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM ...